Digestive Diseases and Sciences

, Volume 60, Issue 8, pp 2280–2286 | Cite as

The Inappropriate Prescription of Oral Proton Pump Inhibitors in the Hospital Setting: A Prospective Cross-Sectional Study

  • Orlaith B. KellyEmail author
  • Catherine Dillane
  • Stephen E. Patchett
  • Gavin C. Harewood
  • Frank E. Murray
Original Article


Proton pump inhibitors (PPIs) are used to treat upper gastrointestinal tract disorders. Their efficacy and perceived safety have led to widespread prescription. This is not without effect, in terms of adverse events and resource utilization.


To prospectively assess oral PPI prescription in hospitalized patients.


PPI prescription in consecutive hospitalized patients was assessed. Indication and dose were assessed by patient interview and medical record review. Comparisons with current published prescribing guidelines were made.


Four hundred and forty-seven patients were included. 57.5 % were prescribed PPIs. 26.8 % prescriptions were for inappropriate or unclear indications. 68.4 % were on higher doses than guidelines recommended, of which 41.6 % could have undergone dose reduction, and 26.5 % discontinued. In a multivariate analysis, age, gender, and length of stay had no association with PPI prescription. Although aspirin use was appropriately associated with PPI prescription (RR: 1.8, 95 % CI 1.127–3.69; p < 0.05), the PPI was often given at higher than recommended doses (p < 0.001). This may reflect older age and multiple risk factors in this subset. Surgical patients commenced more PPIs and at higher dosages (p < 0.001). Omeprazole and lansoprazole were most often inappropriately prescribed (p < 0.01, p < 0.001, respectively).


Inappropriate PPI therapy is still a problem in hospitals, though it appears to be at a lower level compared with previous studies. Awareness of evidence-based guidelines and targeted medicine reconciliation strategies are essential for cost-effective and safe use of these medications.


Proton pump inhibitors Inappropriate prescribing Prescribing patterns Physician Inpatients 



Proton pump inhibitor


Nonsteroidal anti-inflammatories


Peptic ulcer disease


Gastro-esophageal reflux disease




Conflict of interest



  1. 1.
    Wallander MA, Johansson S, Ruigómez A, Rodríguez LAG, Jones R. Dyspepsia in general practice: incidence, risk factors, comorbidity and mortality. Oxford J Med Family Pract. 2007;24:403–411.CrossRefGoogle Scholar
  2. 2.
    Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292:1955–1960.PubMedCrossRefGoogle Scholar
  3. 3.
    Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol. 2008;103:2308–2313.Google Scholar
  4. 4.
    Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests. J Cardiovasc Pharmacol. 2010;56:532–539.PubMedCrossRefGoogle Scholar
  5. 5.
    IMS Health Report. Leading therapy classes by global pharmaceutical sales.,2777,6025_80528184_80530441,00.html; 2006.
  6. 6.
    National Health Service. PACT centre pages. Drugs for dyspepsia.; 2006.
  7. 7.
    van Vliet EP, Otten HJ, et al. Inappropriate prescription of proton pump inhibitors on two pulmonary medicine wards. Eur J Gastroenterol Hepatol. 2008;20:608–612.PubMedCrossRefGoogle Scholar
  8. 8.
    Choudhry MN, Soran H, et al. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM. 2008;101:445–448.PubMedCrossRefGoogle Scholar
  9. 9.
    National Institute for Clinical Excellence. Dyspepsia: managing dyspepsia in adults in primary care. London: NICE; 2004.Google Scholar
  10. 10.
    BNF no. 66, September 2013–March 2014 ISBN-13: 978-0857110855.Google Scholar
  11. 11.
    McGowan B, Bennett K, Tilson L, Barry M. Cost effective prescribing of proton pump inhibitors (PPI’s) in the GMS Scheme. Ir Med J. 2005;98:78–80.PubMedGoogle Scholar
  12. 12.
    Molloy D, Molloy A, O’Loughlin C, Falconer M, Hennessy M. Inappropriate use of proton pump inhibitors. Ir J Med Sci. 2010;179:73–75. doi: 10.1007/s11845-009-0426-1.
  13. 13.
    Thomas L, Culley EJ, Gladowski P, Goff V, Fong J, Marche SM. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm. 2010;16:122–129.PubMedGoogle Scholar
  14. 14.
    Targownik LE, Metge C, et al. The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use. Am J Gastroenterol. 2007;102:942–950.PubMedCrossRefGoogle Scholar
  15. 15.
    Kaye K, Easton-Carter K, Brien J, Day R. An investigation of hospital prescribing of proton pump inhibitors[Internet]. Sydney: NSW Therapeutic Assessment Group.; 2001.
  16. 16.
    Mat Saad AZ, Collins N, Lobo MM, O’Connor HJ. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract. 2005;59:31–34.PubMedCrossRefGoogle Scholar
  17. 17.
    Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336:2.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Campbell F, Karnon J, Czoski-Murray C, Jones R. A systematic review of the effectiveness and cost-effectiveness of interventions aimed at preventing medication error (medicines reconciliation) at hospital admission. The University of Sheffield, School of Health and Related Research (ScHARR). J Eval Clin Pract. 2009;15:299–306.PubMedCrossRefGoogle Scholar
  19. 19.
    Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G. A cost-effectiveness analysis of prescribing strategies in the management of gastroeoesophageal reflux disease. Am J Gastroenterol. 2000;95:395–407.PubMedCrossRefGoogle Scholar
  20. 20.
    Wilcox CM, Aillison J, Benzuly K, Borum M, Cryer B, Grosser T. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin AGA Institute. Clin Gastro Hepatol. 2006;4:1082–1089.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Orlaith B. Kelly
    • 1
    Email author
  • Catherine Dillane
    • 1
  • Stephen E. Patchett
    • 1
  • Gavin C. Harewood
    • 1
  • Frank E. Murray
    • 1
  1. 1.Department of GastroenterologyBeaumont HospitalDublin 9Ireland

Personalised recommendations